Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens.
Ontology highlight
ABSTRACT: Chronic hepatitis B virus (HBV) infection affects 240 to 300 million people worldwide. In the nucleus of infected hepatocytes, the HBV genome is converted to covalently closed circular DNA (cccDNA), which persists and serves as a transcriptional template for viral progeny. Therefore, a long-term cure for chronic HBV infection will require elimination of cccDNA. Although currently available nucleos(t)ide analogues (eg, tenofovir disoproxil fumarate, tenofovir alafenamide, entecavir) effectively control HBV replication, they are seldom curative (functional cure rate ∼10%) and require lifelong treatment for most patients. As such, antiviral agents with novel mechanisms of action are needed. Active site polymerase inhibitor nucleotides (ASPINs) noncompetitively distort the HBV polymerase activ
SUBMITTER: Gish RG
PROVIDER: S-EPMC9703507 | biostudies-literature | 2022 Jan-Dec
REPOSITORIES: biostudies-literature
ACCESS DATA